Trial intelligence / Profile preview

ACZ885 plus methotrexate versus methotrexate alone in early rheumatoid arthritis

NL-OMON30757Phase 2Active, not recruiting

Sponsor
Novartis
Start
Jul 2007
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ACZ885 + methotrexate with placebo + methotrexate (2 arms). Primary endpoint: ACR50 response at 26 weeks. Started Jul 2007; status: active, not recruiting.

02

Drugs

canakinumabmethotrexate
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on NL-OMON30757.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON30757.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call